News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

  • Dana-Farber investigators receive $13.3 million in funding to study whether some groups of patients with DCIS who do not benefit from standard treatment, could be effectively managed with surveillance alone.

Tags: BreastCancer

  • Dana-Farber Cancer Institute today announced an immuno-oncology collaboration with potential applicability in a wide range of oncology indications with Array BioPharma.

Tags: Partnerships, Immunotherapy

  • Researchers found a way of differentiating angiocentric gliomas from other low-grade pediatric brain tumors and developed a pathological test that will help children avoid unnecessary and potentially damaging additional therapies.

Tags: BasicResearch, ChildhoodCancer, BrainTumors

  • Clinical genomic sequencing is feasible in pediatric oncology and can be used to recommend therapy or pinpoint diagnosis in children with solid tumors according to research led by Dana-Farber/Boston Children's Cancer and Blood Disorders Center. The findings, published in JAMA Oncology, represent a significant step in making precision medicine available to children with cancer.

Tags: ChildhoodCancer, TargetedTherapy, Genetics

  • Dana-Farber Cancer Institute is joining 69 of the nation's leading cancer centers in the call for increased HPV vaccination for the prevention of cancer.

Tags: CervicalCancer, Prevention, GynecologicCancers

  • Research by Dana-Farber scientists reveals genes with monoallelic expression are an important source of genetic diversity among people and also may help explain the genetic variation among cancer cells in a tumor.

Tags: BasicResearch, Genetics

  • Three Dana-Farber researchers, writing in a special issue of JAMA published today, make the case for policies and practices that give terminally ill patients more control over how and where they will die.

Tags: ColonCancer, EndOfLife, LungCancer

  • Dana-Farber researchers identify an overactive genetic regulator that could aid in developing strategies to combat drug resistance in ovarian cancer.

Tags: BasicResearch, OvarianCancer, GynecologicCancers

  • Dana-Farber researchers uncover first potential targeted drug for triple-negative breast cancer as well as vulnerability that could be exploited to slow or prevent the development of resistance to BET-inhibiting drugs.

Tags: BasicResearch, BreastCancer

  • New treatments for leukemia, colorectal cancer, brain cancer, lung cancer and breast cancer topped the list of most important research and clinical developments at Dana-Farber in 2015.

Tags: BreastCancer, ColonCancer, LungCancer, Leukemia, BrainTumors

Showing 1-10 of 656 items